Gilead expands lenacapavir licenses: Gilead Sciences stock has 6.53 percent upside
Published on 10/01/2026 at 10:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead expanded its lenacapavir access strategy on September 16, 2026, while Gilead Sciences stock had a Lang & Schwarz price of EUR 131.82 in trading on October 1, 2026. According to Gilead Sciences, six royalty-free licensing agreements now cover 120 high-incidence countries for investigational once-yearly lenacapavir for HIV prevention. MarketBeat reported an average analyst target of USD 158.78, which stood 6.53 percent above the USD 149.05 primary-exchange quote on September 30, 2026.
Lenacapavir reaches 120 countries
The licensing expansion is designed to support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 study continues. The once-yearly formulation remains investigational, so the commercial opportunity depends on clinical results and regulatory decisions rather than on the licensing framework alone.
The announcement builds on Gilead's broader access program for twice-yearly lenacapavir. The company said its planned no-profit supply program had expanded from 2 million people to up to 3 million people through 2028, adding a concrete scale target to the access strategy.
Revenue beats the second-quarter estimate
Gilead's second-quarter revenue was USD 7.80 billion, compared with the USD 7.40 billion consensus estimate, and revenue increased 10.60 percent year over year. MarketBeat reported adjusted EPS of USD -6.75 against consensus of USD -7.25 for the latest quarterly results, a USD 0.50 favorable variance.
The earnings comparison gives the stock a stronger operating reference than the licensing announcement alone. However, the adjusted loss and the investigational status of once-yearly lenacapavir keep execution and regulatory progress central to the valuation discussion.
Analyst target stays above the quote
MarketBeat reported on September 10, 2026 that HSBC raised its target from USD 155.00 to USD 175.00 and maintained a buy rating. A separate MarketBeat consensus on September 26, 2026 counted 29 analysts, including 23 buy ratings, five holds and one strong buy rating, with an average target of USD 158.78.
Gilead stock holds its market range
Gilead's primary listing is on Nasdaq, where the last finance quote was USD 149.05 on September 30, 2026 at 4:00 p.m. ET. The 52-week range was USD 108.46 to USD 157.29, and market capitalization stood at USD 184.8 billion on that date. In Germany, the stock was trading at EUR 131.82 at Lang & Schwarz on October 1, 2026 at 10:32 a.m. CEST, up 0.60 percent versus the prior close of EUR 131.04. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- WKN: 885823
- Ticker: GILD
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 1, 2026, 10:32 a.m. CEST): EUR 131.82
- Change versus prior close: plus 0.60 percent
- Prior close Lang & Schwarz (September 30, 2026): EUR 131.04
- Market capitalization: USD 184.8 billion (as of September 30, 2026)
- 52-week range: USD 108.46-157.29 (as of September 30, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
